Furthermore, the specific effect of GIP on intestinal parameters has been overshadowed by its insulinotropic effects, and it is important to consider the potent effect of not only GIP but also GIP receptor antagonists on splanchnic blood flow during the implementation of GLP‐1/GIP receptor co‐agonists in the treatment of metabolic diseases (Jastreboff et al., 2022; Rosenstock et al., 2021). Here, GCG is linked to metabolic disease.